Clinical trials: Diabetes Type I
Type 2 Diabetes Mellitus (T2DM)
Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy Volunteers
This is a randomized, open, single-dose, crossover-design, phase I study to evaluate the pharmacokinetics and safety after co-administration of L03RD1 and L03RD2 or administration of L03TD1 in healthy volunteers.
- Trial name
- NCT07533539
- Testing
- L03RD1, L03RD2, L03TD1
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Celltrion
Diabetes Mellitus Type 1
HOME-AHCL: Home-Based Implementation of an Advanced Hybrid Closed-Loop System With Telemonitoring in Type 1 Diabetes
The goal of this prospective, single-arm observational study is to characterise a home-based setup and telemonitoring care model for an advanced hybrid closed-loop insulin pump system (Tandem Control-IQ) in adults with type 1…
- Trial name
- HOME-AHCL (NCT07492992)
- Where
- 3 sites in Spain
- Volunteers
- 80 people
- Sponsor
- Air Liquide Healthcare Spain
Type 1 Diabetes
Adaptation of Insulin Delivery Settings to Improve Clinical Outcomes With AID Use
Obtain preliminary safety and performance data on a settings initialization and adaptation algorithm used in conjunction with closed-loop control.
- Trial name
- NCT05204134
- Testing
- Automated Insulin Delivery Settings Initialization and Adaptation Algorithm
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type1 Diabetes Mellitus
A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)
The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes.
- Trial name
- NCT03367390
- Testing
- AID System, Insulin Lispro
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes
This study will look into testing a new medicine called NNC0363-1063 which may be used to treat people with diabetes. The study consists of three parts: Part 1 is a single ascending dose (SAD) study that comprises two subtypes…
- Trial name
- NCT06685185
- Testing
- NNC0363-1063, Insulin degludec, Insulin detemir
- Where
- Germany
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus
Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D
This is a randomized, open-label, active-controlled, single-dose, 3-treatment, 3-period, 3-way crossover, comparative PD and PK inpatient study in adults with T1D.
- Trial name
- NCT04074317
- Testing
- PRAM9, Regular Insulin + Pramlintide, Regular Insulin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Xeris Pharmaceuticals
Type II Diabetes Mellitus
Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)
The purpose of the study is to evaluate the absorption, distribution, metabolism and excretion of AZD1656 after administration of a single oral dose of 14C-labelled AZD1656 solution in male Type 2 Diabetes Mellitus patients.
- Trial name
- ADME (NCT00960791)
- Testing
- AZD1656
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus
Heparinized Islets in Clinical Islet Transplantation
In this study the islets will be surface modified to carry immobilised heparin (Corline Heparin Conjugate) prior to transplantation.
- Trial name
- NCT00678990
- Testing
- Transplantation of islets with heparin coating
- Where
- 2 sites in Sweden
- Volunteers
- 10 people
- Sponsor
- Corline Biomedical AB
Diabetes, Diabetes Mellitus, Type 1
Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos
This trial is conducted in Europe. The aim of this trial is to evaluate the effect of Levemir® (insulin detemir) on glycaemic control, weight and incidence of hypoglycaemic events in insulin treated subjects with type 1 or type 2…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542489
- Testing
- insulin detemir, insulin aspart, human soluble insulin
- Where
- Slovakia
- Volunteers
- 480 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose
The procurement of blood for SMBG, usually via a finger stick, is considered by many patients to be the most painful portion of diabetes therapy.
- Trial name
- NCT00741390
- Testing
- BD/33G, OTM / 33G, OTU/28G
- Where
- 4 sites in United States
- Volunteers
- 250 people
- Sponsor
- Becton, Dickinson and Company
Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
Twiist Postmarket Surveillance Study for Type 1 Diabetes
The goal of this surveillance study is to collect real-world data on adults and youth with type 1 diabetes (T1D) using twiist(TM) for insulin delivery.
- Trial name
- twiist-PS (NCT07356089)
- Testing
- twiist Automated Insulin Delivery System
- Where
- United States
- Volunteers
- 1,875 people
- Sponsor
- Deka Research and Development
Diabetic Nephropathy
Effect of Pyridorin in Patients With Diabetic Nephropathy
The primary objective of the study is to evaluate the safety and tolerability of Pyridorin (pyridoxamine dihydrochloride) 50 mg given orally twice daily in patients with diabetic kidney disease.
- Trial name
- NCT00320060
- Testing
- Pyridorin (pyridoxamine dihydrochloride)
- Volunteers
- 128 people
- Sponsor
- BioStratum
Diabetic Macular Edema, Macular Edema
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema.
- Conditions
- Diabetic Macular Edema, Macular Edema, Type 2 Diabetes With Diabetic Macular Edema, Type 1 Diabetes With Diabetic Macular Edema
- Trial name
- NCT04187443
- Testing
- MS-553
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Diabetes Mellitus, Type 1
Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.
The aim of this trial is to evaluate the efficacy and safety of insulin detemir using the 2400 nmol/mL formulation to optimise dosing in subjects with type 1 diabetes on a basal (once daily)-bolus regimen.
- Trial name
- NCT03220425
- Testing
- Insulin detemir, NPH insulin
- Where
- 93 sites in Australia, Belgium and 8 more
- Volunteers
- 752 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus
The purpose of this two-part multiple ascending dose study is to evaluate the safety and tolerability of multiple doses of MHS552 in adults with type 1 diabetes mellitus.
- Trial name
- NCT05272059
- Testing
- MHS552
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Type I
12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.
The purpose of this study is to compare the safety of HMR 1964 and insulin aspart when used in external pumps with respect to catheter occlusions, GHb assessment, insulin doses, blood glucose parameters, hypoglycemic episodes…
- Trial name
- NCT00046150
- Testing
- Insulin glulisine (HMR1964)
- Where
- 3 sites in France, Germany and 1 more
- Volunteers
- 59 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Asia, Europe, Japan and South America. The aim of the trial is to compare the efficacy, safety and tolerability of NN1250 (insulin degludec ([Deg]) with insulin detemir (IDet), both combined with…
- Trial name
- BEGIN™ (NCT01074268)
- Testing
- insulin degludec, insulin detemir, insulin aspart
- Where
- 69 sites in Argentina, Brazil and 6 more
- Volunteers
- 456 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
The purpose of this study is to assess the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of 3 milligrams (mg) glucagon (glucagon nasal powder) administered nasally compared with commercially available…
- Trial name
- NCT01994746
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 8 sites in United States
- Volunteers
- 77 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Pivotal Omnipod Horizon™ Automated Glucose Control System
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting and…
- Trial name
- NCT04196140
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 16 sites in United States
- Volunteers
- 240 people
- Sponsor
- Insulet Corporation
Type 2 Diabetes
A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG).
- Trial name
- NCT01976858
- Testing
- PEX168
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.